The future of NT-proBNP testing in primary care

Поделиться
HTML-код
  • Опубликовано: 12 сен 2024
  • Looking to the future, experts predict that NT-proBNP will be a marker for identifying symptoms of heart failure at an even earlier stage in the primary care setting.
    To learn more about biomarkers and the role they play in the diagnosis and treatment of heart failure, visit www.roche.com/...
    Subscribe to our RUclips channel now: www.youtube.co...
    Get in touch with us:
    www.roche.com/
    / rochecareers
    / roche
    / roche
    Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
    Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.
    For more information and insights visit: www.roche.com/

Комментарии • 1